Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
The purpose of this study is to determine if 48 weeks of therapy with Pegylated Interferon Lambda plus Ribavirin is effective and safe for a treatment of chronic hepatitis C (CHC) compared to therapy with Pegylated Interferon Alfa-2a plus Ribavirin.
Epistemonikos ID: 2d690fd11747a438c4a3f56c1f300b859bd47045
First added on: Mar 23, 2020